Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Rosetta, Venganza, Alnylam, and More


Title: Compositions and Methods to Treat Asthma

Patent Number: 8,461,125

Filed: Aug. 13, 2010

Inventor: Michael Grunstein, Children’s Hospital of Philadelphia

The invention, the patent’s abstract states, relates to “compositions and methods for the treatment of asthma. The compositions can be, for example, [an] siRNA directed to CD23. The invention also provides a method of treating asthma with a formulation for in vivo delivery of a CD23 siRNA to inhibit IgE binding in a patient.”

Title: microRNAs and Uses Thereof

Patent Number: 8,461,315

Filed: March 10, 2010

Lead Inventor: Isaac Bentwich, Rosetta Genomics

The invention, the patent’s abstract states, relates to “polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.”

Title: Nanoparticles for Delivery of Bioactive Agents

Patent Number: 8,461,316

Filed: Sept. 8, 2010

Lead Inventor: Hsing-Wen Sung, GP Medical (National Tsing Hu University)

“The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one DNA, RNA, or bioactive agent characterized with a positive surface charge and their enhanced efficiency for gene delivery and bioactive agent delivery,” the patent’s abstract states.

Title: siRNA Targeting Connective Tissue Growth Factor

Patent Number: 8,461,326

Filed: Feb. 14, 2012

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF.”

Title: Methods and Materials for Conferring Resistance to Pests and Pathogens of Plants

Patent Number: 8,461,416

Filed: June 28, 2011

Inventor: Charles Niblett, Venganza

The invention comprises “methods and materials for conferring pest resistance to plants,” the patent’s abstract states. “Plants are transformed with a silencing construct homologous to a gene of a plant pest that is essential for the survival, development, or pathogenicity of the pest. This results in the plant producing RNAi to the selected gene, which, when ingested by the pest, results in silencing of the gene and a subsequent reduction of the pest's ability to harm the plant. In other embodiments, the pest's reduced ability to harm the plant is passed on to pest progeny. Methods and materials for de-pathogenesis of pests is also provided.”

Title: Compositions for Inhibiting Gene Expression and Uses Thereof

Application Number: 20130142778

Filed: March 25, 2011

Lead Inventor: Sudhir Agrawal, Idera Pharmaceuticals

The invention, the patent application’s abstract states, relates to “efficacious miRNA-blocking compounds. The inventors have discovered new structural features that … improve the efficacy of miRNA blocking molecules … [including] the presence of multiple 3' ends and a linker at the 5' ends. … These features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability … [and] this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.”

Title: Nucleic Acid/Polysaccharide Complex

Application Number: 20130142832

Filed: Aug. 10, 2011

Lead Inventor: Kazuo Sakurai, NapaJen Pharma

The invention relates to a “highly stable nucleic acid-polysaccharide complex of an siRNA and schizophyllan,” the patent application’s abstract states. “A nucleic acid-polysaccharide complex is formed by adding polydeoxyadenine in which at least part of the phosphodiester link portion is phosphorothioated to an siRNA and allowing the siRNA and schizophyllan to form a complex.”

Title: Methods and Compositions for Treating Prostate Cancer

Application Number: 20130142875

Filed: Nov. 14, 2012

Lead Inventor: Amotz Shemi, Silenseed

The patent application, its abstract states, claims the “treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents.”

Title: Methods and Compositions Involving miRNA and miRNA Inhibitor Molecules

Application Number: 20130143945

Filed: Feb. 7, 2013

Lead Inventor: David Brown, Asuragen

The invention, the patent application’s abstract states, relates to “methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules … [as well as] methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.”

Title: Therapeutic Compositions

Application Number: 20130144048

Filed: Sept. 25, 2012

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

The patent application, its abstract states, relates to “therapeutic siRNA agents and methods of making and using the agents.”